Adjuvant Technology

ImevaX validates a new mucosal adjuvant in the clinic

In vaccine research, there is a longstanding interest in developing an effective, safe and well defined mucosal adjuvant.

As part of our lead product IMX101, we at ImevaX bring a novel mucosal adjuvant into the clinic. The adjuvant directs the immune response to the site of a Helicobacter pylori infection: the stomach. Due to its novel mode-of-action, ImevaX’ adjuvant will be the key in future vaccine development.

The Mucosal Adjuvant Is A Fusion Protein With Two Domains

Our adjuvant has two parts with distinct functions: the targeting moiety delivers the adjuvant to selected immune cells, while the activating moiety enables them to boost the immune response.

After proven safe in preclinical studies, the adjuvant is currently validated in a phase I clinical trial as part of the vaccine IMX101. Nevertheless, this adjuvant can also be used against other pathogens.

Based on this first-generation mucosal adjuvant, we are currently developing an enhanced second-generation.